Calypso Biotech picks up Series A funding
Calypso Biotech, a Dutch developer of therapeutic antibodies for autoimmune diseases, has secured 20 million euros in Series A financing. The lead backers were Gilde Healthcare and Inkef Capital.
20 February 2019•1 min read
